Sudeep Pharma Limited
₹1,066.70-₹64.25 (-5.7%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹7,027 Cr
- P/E
- 73.5x
- EV / EBITDA
- 49.9x
- Revenue
- ₹357 Cr
- Net margin
- 28.5%
- ROCE
- 33.8%
Price chart
Technical chartScreen technicals →+37.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -11.5%
- 3M
- +24.5%
- 6M
- +50.6%
- 1Y
- +37.9%
- 5Y
- +37.9%
52-week range
Day change -₹64.25 (-5.7%) from ₹1,131 to ₹1,067 · Last close Oct 30, 2026
AI Summary
Indian StockStrengths1
- Healthy return on equity of 29.3%
Concerns1
- Negative free cash flow (₹33 Cr)
Rule-based from financial data. Not advice.
About the company
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America.
Read moreShow less
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends to meet the needs across functional foods, dietary supplements, infant and clinical nutrition, fast-moving consumer goods, and convenience food formulations. In addition, the company is involved in manufacturing, developing, buying, selling, importing, exporting, trading, agency, testing, distributing, consigning, stocking, registering, packing, marketing, refining, and processing of pharmaceuticals, nutraceutical and nutrition products, food ingredients, mineral and vitamin blends, or premixes for infant, human and animal nutrition, and other chemical and healthcare products. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.
- Sector
- Healthcare
- Shares outstanding
- 11.3 Cr shares
- ISIN
- INE0QPI01025
- BSE code
- 544619
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹7,027 Cr
- P/E
- 73.5x
- EV / EBITDA
- 49.9x
- EV / Sales
- 20.4x
- P/S
- 20.4x
- Earnings yield
- 1.4%
- 52-week high
- ₹1,342.95
- 52-week low
- ₹530.30
Profitability
- Operating margin
- 38.7%
- Net margin
- 28.5%
- EBITDA margin
- 41.0%
- ROE
- 29.3%
- ROCE
- 33.8%
- ROA
- 21.7%
- Dividend payout
- 0.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 6.1%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹357 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹141 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 41.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -2.0%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹59.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 40.5%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.4%
Solvency and efficiency
- Current ratio
- 5.55
- Debt / Equity
- 0.18
- Debt / Assets
- 0.13
- Debt / EBITDA
- 0.43
- Interest coverage
- 33.25
- Financial leverage
- 1.35
- CFO / Net profit
- 0.60
- Cash / Market cap
- 4.0%
- Cash per share
- ₹24.92
- Asset turnover
- 0.76
- Fixed asset turnover
- 3.58
- Capital intensity
- 0.28
- Debtor days
- 150 days
- Inventory turnover
- 2.79
- Cash conversion cycle
- 182 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹27 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹224 Cr |
| Sales | Operating profit | ₹133 Cr |
| Operating profit | Interest | ₹6 Cr |
| Operating profit | Depreciation | ₹6 Cr |
| Operating profit | Profit before tax | ₹121 Cr |
| Other income | Profit before tax | ₹8 Cr |
| Profit before tax | Tax and other | ₹33 Cr |
| Profit before tax | Net profit | ₹96 Cr |
Revenue and net profit
Revenue grew 3.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹218 Cr | ₹35 Cr |
| FY2022 | ₹345 Cr | ₹52 Cr |
| FY2023 | ₹404 Cr | ₹67 Cr |
| FY2024 | ₹344 Cr | ₹98 Cr |
| FY2025 | ₹357 Cr | ₹96 Cr |
Cash flows
FY2025: ₹59.0 Cr from operations, -₹33.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹36 Cr | -₹9 Cr |
| FY2022 | -₹5 Cr | -₹33 Cr |
| FY2023 | ₹42 Cr | ₹1 Cr |
| FY2024 | ₹59 Cr | ₹18 Cr |
| FY2025 | ₹59 Cr | -₹33 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹357 Cr+3.8%1Y
- Net profit
- ₹96 Cr-2.0%1Y
- Cash from operations
- ₹59 Cr
- Free cash flow
- -₹33 Cr-283.3%1Y
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹357 Cr | ₹133 Cr | — | ₹96 Cr | ₹59 Cr | -₹33 Cr | 22.4% | +3.8% | -2.0% |
Monthly returns
Month-by-month returns of SUDEEPPHRM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹604 Cr |
| Equity capital | ₹10 Cr |
| Reserves | ₹418 Cr |
| Borrowings | ₹123 Cr |
| Other liabilities | ₹54 Cr |
| Assets | ₹604 Cr |
| Fixed assets | ₹105 Cr |
| Capital work in progress | ₹88 Cr |
| Investments | ₹32 Cr |
| Other assets | ₹380 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
SUDEEPPHRM trades at 73.5x earnings against a peer median of 52.6x (a 40% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Sudeep Pharma LimitedSUDEEPPHRMthis companyP/E ↑ premium | ₹7,027 Cr | 73.5x | — | 29.3% | 49.9x |
| Sequent Scientific LimitedVIYASH | ₹8,288 Cr | 531.0x | 4.1x | 0.1% | 633.5x |
| Marksans Pharma Ltd.MARKSANS | ₹7,873 Cr | 32.7x | 5.3x | 11.0% | 38.1x |
| Akums Drugs and Pharmaceuticals LimitedAKUMS | ₹6,983 Cr | 50.9x | 2.9x | -114.6% | -133.2x |
| Aarti Pharmalabs LimitedAARTIPHARM | ₹6,923 Cr | 28.3x | 3.6x | 12.4% | 19.5x |
| PARK MEDI WORLD LIMITEDPARKHOSPS | ₹6,504 Cr | 906.0x | — | 7.0% | 214.8x |
| FDC Ltd.FDC | ₹6,387 Cr | 27.0x | 2.6x | 14.6% | 14.2x |
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDYATHARTH | ₹6,186 Cr | 67.3x | 3.9x | 10.0% | 45.5x |
| Kovai Medical Center & Hospital LtdKOVAI | ₹6,071 Cr | 26.6x | 5.1x | 20.2% | 17.2x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
SUDEEPPHRM since 1 January, against earlier years.
Historical volatility
SUDEEPPHRM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 21.0% |
| FY2022 | 20.0% |
| FY2023 | 22.0% |
| FY2024 | 39.0% |
| FY2025 | 37.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹357 Cr |
| Costs | |
| Interest | ₹6 Cr |
| Expenses | ₹224 Cr |
| Operating profitOperating Profit | ₹133 Cr |
| Other income and charges | |
| Profit before tax | ₹129 Cr |
| Tax | |
| Net profitNet Profit | ₹96 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹604 Cr |
| Equity capitalEquity Capital | ₹10 Cr |
| Reserves | ₹418 Cr |
| Borrowings | ₹123 Cr |
| Other liabilitiesOther Liabilities | ₹54 Cr |
| AssetsTotal Assets | ₹604 Cr |
| Fixed assetsFixed Assets | ₹105 Cr |
| Capital work in progressCWIP | ₹88 Cr |
| Investments | ₹32 Cr |
| Other assetsOther Assets | ₹380 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹59 Cr |
| Investing cash flowCash from Investing Activity | -₹92 Cr |
| Financing cash flowCash from Financing Activity | ₹54 Cr |
| Change in cashNet Cash Flow | ₹22 Cr |
Learn while you research
Academy chapters picked for Sudeep Pharma Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 73.5, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read